Key Takeaway: Nurix is focused on developing innovative therapies through targeted protein degradation. The company is advancing its multi-modal portfolio to combat cancer and autoimmune diseases. Their approach includes automated and integrated direct-to-biology screening, which may enhance drug discovery processes.
Price reaction · baseline $23.83 (2024-09-10T14:58:00.000Z) · hit during market hours · clean, no other NRIX news in the window
day 0 close · peak
+2.5%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is dedicated to translating scientific insights into therapies.
The company is advancing a multi-modal portfolio of assets.
Focus on targeted protein degradation could lead to breakthroughs.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on?
Nurix is dedicated to developing therapies for cancer and autoimmune diseases.
What approach does Nurix use for drug discovery?
Nurix employs automated and integrated direct-to-biology screening.
What type of portfolio does Nurix have?
Nurix has a multi-modal portfolio of wholly owned and partnered assets.